WFA
ACRS icon

Wipfli Financial Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Wipfli Financial Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
+68
New +$1.07K ﹤0.01% 2356

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Wipfli Financial Advisors's ACRS Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Aclaris Therapeutics (ACRS) in Q3 2022: 68 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2356 among its holdings.

127 funds tracked by Wall St. Rank hold ACRS as of Q3 2022.

  • Wipfli Financial Advisors held 68 shares of Aclaris Therapeutics worth $1K as of Q3 2022.
  • Aclaris Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Aclaris Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2356 holding.
  • 127 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.